Country: Ирска
Језик: Енглески
Извор: HPRA (Health Products Regulatory Authority)
DROSPIRENONE, ETHINYLESTRADIOL
Rowex Ltd
G03AA12
DROSPIRENONE, ETHINYLESTRADIOL
0.03 / 3 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Progestogens and estrogens, fixed combinations
Authorised
2012-09-07
PACKAGE LEAFLET: INFORMATION FOR THE USER FREEDO & PLACEBO 0.03 MG/3 MG FILM-COATED TABLETS Ethinylestradiol/Drospirenone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do no pass it on to others. It may harm them even if their signs of ilness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IMPORTANT THINGS TO KNOW ABOUT COMBINED HORMONAL CONTRACEPTIVES (CHCS): • They are one of the most reliable reversible methods of contraception if used correctly • They slightly increase the risk of having a blood clot in the veins and arteries, especially in the first year or when restarting a combined hormonal contraceptive following a break of 4 or more weeks • Please be alert and see your doctor if you think you may have symptoms of a blood clot (see section 2 “Blood clots”) WHAT IS IN THIS LEAFLET: 1. What Freedo & Placebo is and what it is used for 2. What you need to know before you take Freedo & Placebo 3. How to take Freedo & Placebo 4. Possible side effects 5. How to store Freedo & Placebo 6. Contents of the pack and other information 1. WHAT FREEDO & PLACEBO IS AND WHAT IT IS USED FOR Freedo & Placebo is a contraceptive pill and is used to prevent pregnancy. Each of the 21yellow tablet contains a small amount of two different female Прочитајте комплетан документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Freedo & Placebo 0.03 mg/3 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION YELLOW TABLETS (ACTIVE TABLETS): Each film-coated tablet contains 0.03 mg of ethinylestradiol and 3 mg of drospirenone Excipient with known effect Each tablet contains 62 mg lactose monohydrate WHITE TABLETS (PLACEBO TABLETS) The tablet does not contain active substances Excipient with known effect Each tablet contains 89.5 mg lactose, anhydrous For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. Active tablets: Yellow, round film-coated tablets. Placebo tablets: White, round film-coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oral contraception The decision to prescribe Freedo & Placebo should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Freedo & Placbo compares with other CHCs (see sections 4.3 and 4.4). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology HOW TO TAKE FREEDO & PLACEBO The tablets must be taken every day at about the same time, if necessary with a little liquid in the order shown on the blister pack. Tablet taking is continuous. One tablet is to be taken daily for 28 consecutive days. Each subsequent pack is started the day after the last tablet of the previous pack. Withdrawal bleeding usually starts on day 2-3 after starting the placebo tablets (last row) and may not have finished before the next pack is started. HOW TO START FREEDO & PLACEBO • No preceding hormonal contraceptive use (in the past month) Tablet-taking has to start on day 1 of the woman’s natural cycle (i.e. the first day of her menstrual bleeding). • Changing from a combined hormonal contraceptive (combined oral contraceptive(COC), vaginal ring, or transdermal patch) H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Прочитајте комплетан документ